No Data
No Data
CanSino Biologics Expects Narrower Attributable Loss in 2024
Express News | CanSino Biologics FY Net Income RMB -1,482.7 Million
Is CanSino Biologics (HKG:6185) A Risky Investment?
CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Indonesia
CanSino Biologics Expands Global Reach With Indonesian Vaccine Approval
Express News | CanSino Biologics Inc - Menhycia Obtains Drug Registration Certificate in Indonesia